Trial · NCT02646982

Candesartan's Effects on Alzheimer's Disease And Related Biomarkers

NCT02646982, Phase 2, Completed, Emory University; results first posted 2022-09-29

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Candesartan's Effects on Alzheimer's Disease And Related Biomarkers. Trials, record NCT02646982. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02646982

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Candesartan's Effects on Alzheimer's Disease And Related Biomarkers
NCT number: NCT02646982
Status: Completed
Phases: Phase 2
Enrollment: 77 participants, actual
Lead sponsor: Emory University
Conditions: Mild Cognitive Impairment
Interventions: Placebo, Candesartan
First posted: 2016-01-06
Last updated: 2022-12-01
Results first posted: 2022-09-29

Source ClinicalTrials.gov

Registered outcomes22

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants With a Hypotensive Episode	Up to Month 12	Hypotension is defined as blood pressure \<100/40 mm Hg. Blood pressure was measured according to the American Heart Association guidelines with the subject in the sitting position and rested for 5 minutes. An appropriate cuff size (covering 60% of upper arm length and 80% of arm circumference) was used and correct cuff placement (1-2 inches above the brachial pulse on bare arm) was ensured.
Primary	Number of Participants With Symptoms of Hypotension	Up to Month 12	Participants were asked to report any symptoms of hypotension (dizziness, weakness, fatigue and lightheadedness). All participants were given a telephone number to reach physician 24-hours per day to report symptoms they experience. The number of participants reporting symptoms of hypotension is reported here.
Primary	Number of Participants With Hypotensive Episodes and Symptoms	Up to Month 12	The number of participants with reported episodes hypotension as well as symptoms of hypotension.
Primary	Number of Participants With Elevated Serum Creatinine	Up to Month 12	The levels of creatinine were obtained from blood samples. Elevated serum creatinine is defined as levels \>2.5 milligram per deciliter (mg/dL). Elevated serum creatinine is indicative of decreased renal function.
Primary	Number of Participants With Hyperkalemia	Up to Month 12	The levels of potassium were obtained from blood samples. Hyperkalemia is defined as potassium levels \>5.9 milliequivalent per deciliter (meq/dL). Hyperkalemia is an indication of kidney dysfunction.
Primary	Number of Participants Discontinuing Study Medication	Up to Month 12	The number of participants who discontinued the study medication is presented here.
Secondary	Cerebrospinal Fluid (CSF) Total Tau Levels	Baseline, Month 12	CSF total tau (t-tau) levels were analyzed from CSF samples obtained via lumbar puncture. Normal values for t-tau are \< 450 pg/ml. Elevated levels of t-tau indicate worsening disease.
Secondary	Cerebrospinal Fluid (CSF) of Tau Phosphorylated at Threonine 181 (p-tau181) Levels	Baseline, Month 12	CSF levels of p-tau181 were analyzed from CSF samples obtained via lumbar puncture. P-tau181 is a biomarker that is elevated in persons with Alzheimer's disease. Higher values indicate worsening disease.
Secondary	Cerebrospinal Fluid (CSF) Amyloid Aβ42 Levels	Baseline, Month 12	CSF Aβ42 levels were analyzed from CSF samples obtained via lumbar puncture. Aβ42 is a biomarker for Alzheimer's disease and lower values indicate worsening disease and an increased accumulation of amyloid in the brain.
Secondary	Cerebrospinal Fluid (CSF) Amyloid Aβ40 Levels	Baseline, Month 12	CSF Aβ40 levels were analyzed from CSF samples obtained via lumbar puncture. Lower values indicate worsening disease and an increased brain accumulation of amyloid.

1 to 10 of 22Source ClinicalTrials.gov

See all 22 registered outcomes

Outcomes22

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants With a Hypotensive Episode	Up to Month 12		Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Number of Participants With Symptoms of Hypotension	Up to Month 12		Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Number of Participants With Hypotensive Episodes and Symptoms	Up to Month 12		Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Number of Participants With Elevated Serum Creatinine	Up to Month 12		Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Number of Participants With Hyperkalemia	Up to Month 12		Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Number of Participants Discontinuing Study Medication	Up to Month 12		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Cerebrospinal Fluid (CSF) Total Tau Levels	Baseline, Month 12	This analysis includes participants who had CSF samples collected.	Picograms per milliliter (pg/ml)	LEAST_SQUARES_MEAN
SECONDARY	Cerebrospinal Fluid (CSF) of Tau Phosphorylated at Threonine 181 (p-tau181) Levels	Baseline, Month 12	This analysis includes participants who had CSF samples collected.	pg/ml	LEAST_SQUARES_MEAN
SECONDARY	Cerebrospinal Fluid (CSF) Amyloid Aβ42 Levels	Baseline, Month 12	This analysis includes participants who had CSF samples collected.	pg/ml	LEAST_SQUARES_MEAN
SECONDARY	Cerebrospinal Fluid (CSF) Amyloid Aβ40 Levels	Baseline, Month 12	This analysis includes participants who had CSF samples collected.	pg/ml	LEAST_SQUARES_MEAN

1 to 10 of 22Source ClinicalTrials.gov

See all 22 outcomes

Results by group82

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Number of Participants With a Hypotensive Episode	Candesartan	16	Participants
Number of Participants With a Hypotensive Episode	Placebo	4	Participants
Number of Participants With Symptoms of Hypotension	Candesartan	7	Participants
Number of Participants With Symptoms of Hypotension	Placebo	10	Participants
Number of Participants With Hypotensive Episodes and Symptoms	Candesartan	4	Participants
Number of Participants With Hypotensive Episodes and Symptoms	Placebo	1	Participants
Number of Participants With Elevated Serum Creatinine	Candesartan	0	Participants
Number of Participants With Elevated Serum Creatinine	Placebo	0	Participants
Number of Participants With Hyperkalemia	Candesartan	0	Participants
Number of Participants With Hyperkalemia	Placebo	1	Participants

1 to 10 of 82Source ClinicalTrials.gov

See all 82 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Candesartan	38
Overall Study	STARTED	Placebo	39
Overall Study	COMPLETED	Candesartan	35
Overall Study	COMPLETED	Placebo	37
Overall Study	NOT COMPLETED	Candesartan	3
Overall Study	NOT COMPLETED	Placebo	2

Source ClinicalTrials.gov

Adverse events24

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Dizziness	General disorders	Candesartan	6	38
other	Dizziness	General disorders	Placebo	5	39
other	Fatigue, tiredness, weakness	General disorders	Candesartan	4	38
other	Fatigue, tiredness, weakness	General disorders	Placebo	4	39
other	Headache	General disorders	Candesartan	2	38
other	Headache	General disorders	Placebo	5	39
other	Back pain	Musculoskeletal and connective tissue disorders	Candesartan	2	38
other	Back pain	Musculoskeletal and connective tissue disorders	Placebo	0	39
other	Lightheadedness	General disorders	Candesartan	1	38
other	Lightheadedness	General disorders	Placebo	1	39

1 to 10 of 24Source ClinicalTrials.gov

See all 24 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Candesartan	0	38
Total, all-cause mortality	Placebo	0	39
Total, other adverse events	Candesartan	20	38
Total, other adverse events	Placebo	17	39
Total, serious adverse events	Candesartan	0	38
Total, serious adverse events	Placebo	0	39

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
36440097	DERIVED

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01AG049752	A biomarker-driven trial of angiotensin receptor blockers for prodromal Alzheimer	GOLDSTEIN, FELICIA C.	EMORY UNIVERSITY	NATIONAL INSTITUTE ON AGING	2016 to 2020

Source NIH RePORTER

Trial comparisons8

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Candesartan vs Placebo: Number of Participants With Elevated Serum Creatinine	Trial comparisons
Candesartan vs Placebo: Number of Participants With Hypotensive Episodes and Symptoms	Trial comparisons
Candesartan vs Placebo: Number of Participants With Hyperkalemia	Trial comparisons
Candesartan vs Placebo: Number of Participants With Symptoms of Hypotension	Trial comparisons
Candesartan vs Placebo: Number of Participants With a Hypotensive Episode	Trial comparisons
Candesartan vs Placebo: deaths from any cause	Trial comparisons
Candesartan vs Placebo: Number of Participants Discontinuing Study Medication	Trial comparisons
Candesartan vs Placebo: serious adverse events	Trial comparisons

Tests6

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as	Source
1-Back Task	Secondary outcome	ConductCognition
Category Fluency	Secondary outcome	ConductCognition
Eriksen Flanker Task	Secondary outcome	ConductCognition
Trail Making Test B	Secondary outcome	ConductCognition
Verbal Fluency	Secondary outcome	ConductCognition
Verbal Learning	Secondary outcome	ConductCognition

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02646982

GET https://conductscience.org/api/trials/v1/NCT02646982/registered?page=2

API reference For AI assistants